MC1R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
=== 1997 constitutional crisis === The Cherokee Nation was seriously destabilized in May 1997 in what was variously described as either a nationalist "uprising" or an "anti-constitutional coup" instigated by Joe Byrd, the Principal Chief. Elected in 1995, Byrd became locked in a battle of strength with the judicial branch of the Cherokee tribe. The crisis came to a head on March 22, 1997, when Byrd said in a press conference that he would decide which orders of the Cherokee Nation's Supreme Court were lawful and which were not. A simmering crisis continued over Byrd's creation of a private, armed paramilitary force. On June 20, 1997, his private militia illegally seized custody of the Cherokee Nation Courthouse from its legal caretakers and occupants, the Cherokee Nation Marshals, the Judicial Appeals Tribunal, and its court clerks. The courts demanded the courthouse's return, but Byrd refused. The Federal authorities of the United States initially refused to intervene because of potential breach of tribal sovereignty. Byrd was required to attend a meeting in Washington, D.C. with the Bureau of Indian Affairs, at which he was compelled to reopen the courts. Byrd served the remainder of his term but lost the 1999 election for Principal Chief to Chad Smith. He was later elected to the Tribal Council in 2013. A new constitution was drafted in 1999 that included procedures for voters to remove officials from office, changed the structure of the tribal council, and removed the need to ask the Bureau of Indian Affairs' permission to amend the constitution.
=== Expansion === In 1994, Dane and Travis Boersma struck a deal with a customer, Marty McKenna, which allowed him to open his own Dutch Bros in Medford, about 30 miles away from Grants Pass. McKenna's first stand performed so well that he soon opened up a second one across town. In 1997, the Boersmas brought McKenna on as a partner, hoping he would continue to expand the Medford operations. Two years later, they bought out McKenna's stake in the company. In 1999, Dutch Bros started formally franchising. The company opened its 50th franchised drive-thru location in 2004. That same year, shortly after moving into a new headquarters in Grants Pass, a nearby dumpster fire spread to the building, destroying Dutch Bros roasting equipment, five vehicles, and thousands of pounds of coffee beans. Following this incident, the company continued to expand, and by the end of 2004, operated 61 coffee shops spanning from Northern California to Oregon's Willamette Valley. By 2009, Dutch Bros was running about 135 coffee stands in seven states and generating $50 million in gross annual revenue. Dane Boersma died in 2009 from amyotrophic lateral sclerosis. In 2013, Travis Boersma was featured on the American version of the television show Undercover Boss. Revenues continued to grow into the mid-2010s. The company earned $238 million in systemwide sales in 2015, $350 million in 2016, and $415.3 million in 2017, when over 283 Dutch Bros locations were operating.
== Therapeutics == Several mimetics of ELA have been developed for therapeutic purposes. Amgen has created a camel antibody and a small molecule agonist capable of mimicking the function of ELA towards it cognate receptor APLNR. The latter has entered phase 1 clinical trials for heart failure and acute kidney disease. Bristol Myers Squibb has also created its own small molecule agonist of APLNR. An opinion published in the Lancet in 2019 suggested that ELABELA could be used to treat intrauterine growth restriction and maternal morbidity linked to eclampsia.
Anabolic steroids (most common), which increase muscle mass and physical strength. Stimulants (second most common), which increase excitement and decrease the sensation of fatigue. Examples of well known stimulants include caffeine, cocaine, amphetamine, modafinil, and ephedrine. Caffeine, although a stimulant, has not been banned by the International Olympic Committee or the World Anti Doping Agency since 2004. It has a positive effect on various physical parameters, most of all endurance, but also on velocity, strength, reaction time and specific actions like throwing performance. Other ways of cheating that change the body without using foreign substances include injecting one's own red blood cells as done with doping at the Tour de France, treating blood with UV light or the use of a hyperbaric chamber (not currently banned), and, potentially, gene doping.
Sources: en.wikipedia.org
=== Negotiations fail === Steyn of the Orange Free State invited Milner and Kruger to attend a conference in Bloemfontein. The conference started on 30 May 1899, but negotiations quickly broke down, as Kruger had no intention of granting meaningful concessions, and Milner had no intention of accepting his normal delaying tactics. On 9 October 1899, after convincing the Orange Free State to join him and mobilising their forces, Kruger issued an ultimatum giving Britain 48 hours to withdraw troops from the border of Transvaal, despite the fact the only regular British troops near the border of either republic were 4 companies deployed to defend Kimberley. Otherwise, the Transvaal, allied with the Orange Free State, would declare war. News of the ultimatum reached London on the day it expired. The editor of the Times purportedly laughed out loud when he read it, saying 'an official document is seldom amusing and useful yet this was both'. The Times denounced the ultimatum as an 'extravagant farce' and The Globe denounced this 'trumpery little state'. Most editorials were similar to the Daily Telegraph's, which declared: 'of course there can only be one answer to this grotesque challenge. Kruger has asked for war and war he must have!' Such views were far from those of the British government and the army. Army reform had been a matter of pressing concern since the 1870s, put off because the public did not want the expense of a larger, more professional army and because a large home army was not politically welcome.
=== Linear motifs === Linear motifs are short disordered segments of proteins that mediate functional interactions with other proteins or other biomolecules (RNA, DNA, sugars etc.). Many roles of linear motifs are associated with cell regulation, for instance in control of cell shape, subcellular localisation of individual proteins and regulated protein turnover. Often, post-translational modifications such as phosphorylation tune the affinity (not rarely by several orders of magnitude) of individual linear motifs for specific interactions. Relatively rapid evolution and a relatively small number of structural restraints for establishing novel (low-affinity) interfaces make it particularly challenging to detect linear motifs but their widespread biological roles and the fact that many viruses mimick/hijack linear motifs to efficiently recode infected cells underlines the relevance of this research area.
== Venture capital arm == In early 2021, Dexcom launched Dexcom Ventures, a venture capital arm focused on emerging continuous glucose monitoring technologies and devices measuring the levels of other types of substances and analytes. In practice, Dexcom Ventures has also invested in cybersecurity platforms for the software used in medical devices.
The most notable cell types of sponges are the goblet-shaped cells called choanocytes, so named for their similarity to choanoflagellates. The similarities between these two cells types makes scientists believe that choanoflagellates are the sister taxa to metazoa. The flagella of these cells are what drive the water movement through the sponge body. The cell body of choanocytes is what is responsible for nutrient absorption. In some species these cells can develop into gametes. The Pinacocytes are the cells on the exterior of the sponge that line the cell body. They are tightly packed together and very thin. The mesenchyme lines the region between the pinacocytes and the choanocytes. They contain a matrix composed of proteins and spicules. Archaeocytes are special types of cells, in that they can transform into all of the other cell types. They will do what is needed in the sponge body, such as ingest and digest food, transport nutrients to other cells in the sponge body. These cells are also capable of developing into gametes in some sponge species. The sclerocytes are responsible for the secretion of spicules. In species of sponges that use spongin instead of calcaerous and silicaceous spicules, the sclerocytes are replaced by spongocytes, which secrete spongin skeletal fibres. The myocytes and porocytes are responsible for contraction of the sponge. These contractions are analogous to muscle contractions in other organisms, since sponges do not have muscles. They are responsible for regulating the water flow through the sponge.
Rebellions against Spanish rule had occurred in the empire since the advent of conquest and colonization, but most were either crushed or remained too weak to change the overall situation. The last one that sought outright independence from Spain sprang up around 1810 and culminated in the Colombian Declaration of Independence, issued on 20 July 1810, the day that is now celebrated as the nation's Independence Day. This movement followed the independence of Saint-Domingue (present-day Haiti) in 1804, which provided some support to an eventual leader of this rebellion: Simón Bolívar. Francisco de Paula Santander also would play a decisive role. A movement was initiated by Antonio Nariño, who opposed Spanish centralism and led the opposition against the Viceroyalty. Cartagena became independent in November 1811. In 1811, the United Provinces of New Granada were proclaimed, headed by Camilo Torres Tenorio. The emergence of two distinct ideological currents among the patriots (federalism and centralism) gave rise to a period of instability called the Patria Boba. Shortly after the Napoleonic Wars ended, Ferdinand VII, recently restored to the throne in Spain, unexpectedly decided to send military forces to retake most of northern South America. The viceroyalty was restored under the command of Juan de Sámano, whose regime punished those who participated in the patriotic movements, ignoring the political nuances of the juntas.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.